WORCESTER, Mass., March 26, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that as a result of increased demand, the company plans to pursue the regulatory path for the submission of Generex Oral-lyn(tm) with the veterinary arms of global health agencies for therapeutic use in cats and dogs with diabetes.
